Suomalainen: nothing to disclose, Sami Curtze: nothing to disclose, Tuomas Lumikari: nothing to disclose, Jani Pirinen: nothing to disclose, Daniel Gordin: nothing to disclose, Petra Ijs: nothing to disclose, Sija Rty: nothing to disclose, Mika Lehto: nothing to disclose, Jukka Putaala: nothing to disclose E-Posters - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.06 - CARDIOEMBOLISM & HEART-BRAIN INTERACTIONS P2371 - ESOC25-1381 STROKE UNIT TELEMETRY REVEALS DISTINCT EPISODE DYNAMICS ASSOCIATED WITH ATRIAL FIBRILLATION BURDEN AFTER ACUTE ISCHEMIC STROKE Markus Klammer 1,2,3 , Helena Stengl 1,2,3 , Alexander Nelde 1,3 , Maximilian Schls 1,3 , Andreas Meisel 1,2,3 , Franziska Scheibe 1,4 , Christian Nolte 1,2,3 , Matthias Endres, Christian Meisel 2,3,4 , Jan Scheitz 1,2,3 1 Department of Experimental Neurology - Charite Universittsmedizin Berlin, Berlin, Germany, 2 Center of Stroke Research Berlin, Berlin, Germany, 3 Berlin Institute of Health (BIH), Berlin, Germany, 4 NeuroCure Cluster of Excellence, Charit-Universittsmedizin Berlin, Berlin, Germany Background and Aims: Atrial fibrillation (AF) burden is a key prognostic factor for AF-related first and recurrent stroke, but its characteristics and AF-associated heart rate (HR) in the early post-stroke phase are not well understood
Abbasinejad, MD, for Personalized Tirzepatide Weight Loss Plans in Fayetteville
This is more than the 150 minutes recommended for general health
The vial contains 1,000 mcg
2 The SELECT trial kidney outcomes The SELECT trial tested semaglutide at the Wegovy dose (2.4 mg) in 17,604 people with obesity and cardiovascular disease, without diabetes
Y.DuanX
